StockNews.com began coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a report published on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Stock Up 9.6 %
AEZS stock opened at $2.14 on Tuesday. The company’s 50-day moving average price is $1.99 and its two-hundred day moving average price is $1.90. Aeterna Zentaris has a 12 month low of $1.36 and a 12 month high of $3.30. The firm has a market cap of $10.40 million, a P/E ratio of -0.63 and a beta of 1.57.
Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) last issued its earnings results on Wednesday, March 27th. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.19). The business had revenue of $0.12 million for the quarter. Aeterna Zentaris had a negative return on equity of 63.20% and a negative net margin of 368.01%.
About Aeterna Zentaris
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.
Featured Stories
- Five stocks we like better than Aeterna Zentaris
- Buy P&G Now, Before It Sets A New All-Time High
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- CD Calculator: Certificate of Deposit Calculator
- Hilton Demonstrates Asset Light is Right for Investors
- What Investors Need to Know About Upcoming IPOs
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.